INSULET CORP 8-K

What Happened

• On March 12, 2026, Insulet Corporation (PODD) filed an 8-K and furnished a press release (Exhibit 99.1) announcing a voluntary medical device correction.
• The company said it is too early to determine the exact cost but currently expects to incur up to $40 million of costs related to the correction, all to be incurred in 2026.
• Insulet stated these costs will be excluded from its adjusted (non‑GAAP) results and that it is not changing its previously issued 2026 guidance as a result of the action.

Key Details

• Up to $40 million expected cost, recognized in 2026.
• Costs will be excluded from adjusted (non‑GAAP) results.
• Company is not revising its 2026 guidance at this time.
• Disclosure made via press release filed as Exhibit 99.1 on March 12, 2026.

Why It Matters

• For investors, the item represents a near‑term cash impact (up to $40M) tied to a voluntary product action, but management is signaling no change to underlying 2026 revenue/growth expectations by excluding the charge from adjusted results and leaving guidance unchanged.
• Watch for follow‑up disclosures with more detail on the scope, timing, and any insurance recoveries or additional financial impacts that could affect reported GAAP results and cash flow.